ASTELLAS PHARMA A/S: Financial statements 2025
CVR: 10888638
Source: annual report 2025, Danish Business Authority
01/04/2024 – 31/03/2025
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2025. In 2025, the company reported revenue of EUR 191,027,000 and a net result of EUR 5,705,000 compared with EUR 4,470,000 the year before. That is an increase of 2.2% compared with the year before. The profit margin was 3%. Equity in the 2025 report amounted to EUR 20,814,000. The solvency ratio was 18.9%. The company had 96 employees in the financial year.
- Revenue
- EUR 191,027,000
- Gross Profit
- EUR 24,411,000
- Profit/Loss
- EUR 5,705,000
- Equity
- EUR 20,814,000
- Total Assets
- EUR 109,956,000
- Employees
- 96
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 191M EUR | 24.4M EUR | 5.7M EUR | 20.8M EUR | 96 |
| 2024 | 186.9M EUR | 20.9M EUR | 4.5M EUR | 24.7M EUR | 97 |
| 2023 | 180.8M EUR | 23.1M EUR | 2.1M EUR | 35.3M EUR | 120 |
| 2022 | 179.9M EUR | 26.2M EUR | 6.7M EUR | 58.2M EUR | 120 |
| 2021 | 160.5M EUR | 24.1M EUR | 5.9M EUR | 59.4M EUR | 115 |
Official annual report
How creditworthy is ASTELLAS PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
ASTELLAS PHARMA A/S has won the tender "Amgros 2026 1.450.b" issued by Amgros I/S worth 72,960,000 DKK.
ASTELLAS PHARMA A/S has won the tender "Amgros 2026 1.580.a" issued by Amgros I/S worth 165,000,000 DKK.
As of December 1, 2025, Mark Andree Dekker has joined the board of directors of ASTELLAS PHARMA A/S.
As of December 1, 2025, Morten Auscher has left the board of directors of ASTELLAS PHARMA A/S.
As of December 1, 2025, Mark Andree Dekker is registered as director of ASTELLAS PHARMA A/S.
As of December 1, 2025, Morten Auscher has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
As of March 11, 2025, Morten Auscher has joined the board of directors of ASTELLAS PHARMA A/S.
As of March 11, 2025, Karl Håkan Lennart Widen has left the board of directors of ASTELLAS PHARMA A/S.
As of March 11, 2025, Morten Auscher is registered as adm. dir. of ASTELLAS PHARMA A/S.
As of March 11, 2025, Karl Håkan Lennart Widen has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
About ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.